Cutaneous lymphomas appearing during treatment with biologics: 44 cases from the French Study Group on Cutaneous Lymphomas and French Pharmacovigilance Database

Dequidt, L.; Franck, N.; Sanchez-Peña, Paola; Dalle, S.; Adamski, H.; Boulinguez, S.; Ingen‐Housz‐Oro, Saskia; Ram‐Wolff, Caroline; Boccara, O.; Bonnet, N.; Cortès, Bégonia; Gouraud, A.; Grange, Florent; Corre, Y. Le; Quéreux, G.; Masson, Adèle de; Schmutz, J.‐L.; Skowron, F.; Verneuil, L.; Beylot‐Barry, M.

doi:10.1111/bjd.17834

Cited by 17 publications

(25 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Concerning the 27 psoriatic patients receiving biologicals, 18 patients received only 1 biological therapy (etanercept: 6; adalimumab: 5; infliximab: 4; secukinumab: 2; efalizumab: 1) and 9 patients received more than 1 biological therapy (adalimumab: 5; etanercept: 4; infliximab: 2; ustekinumab: 2; apremilast: 2; efalizumab: 1; secukinumab: 1; alefacept: 1; ixekizumab: 1). One additional recent article could not be included in Table due to the lack of specific data …”

Section: Resultsmentioning

confidence: 99%

“…The ten above-mentioned cases could be lumped together with the other few reported cases in the literature of psoriasiform MF, a rare variant of MF that simulates psoriasis at the onset. [5][6][7][8][9][10] Finally, it must be underlined that recently, Dequidt et al 69 reported six additional psoriatic patients who developed MF during biological therapies, but due to the lack of specific data about each patient, they could not be included in our review. Interestingly, also Dequidt et al 69 concluded that three scenarios are possible: misdiagnosis of MF as psoriasis; true association MF and psoriasis; and MF de novo, occurring mainly in patients treated for rheumatism or inflammatory colitis.…”

Section: Discussionmentioning

confidence: 99%

“…The ten above‐mentioned cases could be lumped together with the other few reported cases in the literature of psoriasiform MF, a rare variant of MF that simulates psoriasis at the onset . Finally, it must be underlined that recently, Dequidt et al . reported six additional psoriatic patients who developed MF during biological therapies, but due to the lack of specific data about each patient, they could not be included in our review.…”

Section: Discussionmentioning

confidence: 99%

“…reported six additional psoriatic patients who developed MF during biological therapies, but due to the lack of specific data about each patient, they could not be included in our review. Interestingly, also Dequidt et al . concluded that three scenarios are possible: misdiagnosis of MF as psoriasis; true association MF and psoriasis; and MF de novo , occurring mainly in patients treated for rheumatism or inflammatory colitis.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Risk of mycosis fungoides in psoriatic patients: a critical review

Biondo

Cerroni

Brunasso

et al. 2020

Acad Dermatol Venereol

View full text Add to dashboard Cite

Psoriasis has been controversially associated with risk of non-Hodgkin lymphoma (NHL) and mycosis fungoides (MF). Also patients who developed MF after systemic treatment for psoriasis have been reported, and some authors suggested that the association between MF and psoriasis is not infrequent. We performed an extensive literature review in order to examine the risk of developing MF in psoriatic patients with a systematic search of the English-language databases. An increased risk for lymphoma overall in psoriatic patients has been found only by three out of seven studies. The risk of developing MF in psoriatic patients has been investigated by different studies in different populations and with different methodologies presenting bias and limitations, and it seems reasonable that misclassification between psoriasis and MF may explain the association reported. In contrast to the large number of psoriatic patients treated with biologicals, only 27 case reports of MF after biological therapy for psoriasis have been reported, and in 10 cases, the initial psoriasis diagnoses were then revised as MF. A true association between MF and psoriasis is possible, but the real incidence and prevalence are still unknown. The reported higher risk of developing MF in psoriatic patients should be reconsidered in the light of the bias of misclassification and the low magnitude reported in previous studies. There is not enough evidence to support a causal relation among biological therapies and MF in psoriatic patients.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Risk of mycosis fungoides in psoriatic patients: a critical review

Biondo

Cerroni

Brunasso

et al. 2020

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…[23][24][25] Iatrogenic immunosuppression in early-stage CTCL leads to rapid and dramatic disease exacerbation, underscoring the importance of an intact adaptive immune system for controlling this lymphoma. [26][27][28] Progression of CTCL is associated with an immunosuppressive, inflammatory tumor microenvironment and a loss in T-cell diversity. 22,[29][30][31] Malignant CD4 + T-cells play a role in reorchestrating the immune system from the protective T H 1 response to the T H 2 response characterized by excessive production of inflammatory cytokines including interleukin (IL)-4, IL-5, and IL-10, 32,33 as well as suppression of IL-2 and IFN-γ.…”

mentioning

confidence: 99%

Immunotherapy for Cutaneous T-Cell Lymphoma: Current Landscape and Future Developments

et al. 2019

View full text Add to dashboard Cite

Mycosis fungoides (MF) and Sézary syndrome (SS) are chronic, progressive primary cutaneous T-cell lymphomas (CTCLs) for which there are no curative treatments. Skin-directed therapies, such as phototherapy, radiation therapy, or topical nitrogen mustard, provide only short-term remissions. Numerous attempts with different chemotherapeutic regimes failed to achieve meaningful clinical responses. Immunotherapy seems to be a promising avenue to achieve long-term disease control in CTCL. There is compelling evidence indicating that MF and SS are immunogenic lymphomas, which can be recognized by the patient’s immune system. However, CTCL uses different strategies to impair host’s immunity, eg, via repolarizing the T-cell differentiation from type I to type II, recruiting immunosuppressive regulatory T-cells, and limiting the repertoire of lymphocytes in the circulation. Many currently used therapies, such as interferon-α, imiquimod, extracorporeal phototherapy, and allogeneic bone marrow transplant, seem to exert their therapeutic effect via activation of the antitumor cytotoxic response and reconstitution of the host’s immune system. It is likely that novel immunotherapies such as immune checkpoint inhibitors, cancer vaccines, and chimeric antigen receptor-T cells will help to manage CTCL more efficiently. We also discuss how current genomic techniques, such as estimating the mutational load by whole genome sequencing and neoantigen calling, are likely to provide clinically useful information facilitating personalized immunotherapy of CTCL.

show abstract

Mycosis fungoides

2020

Skin Lymphoma

View full text Add to dashboard Cite

Cutaneous lymphomas appearing during treatment with biologics: 44 cases from the French Study Group on Cutaneous Lymphomas and French Pharmacovigilance Database

Cited by 17 publications

References 8 publications

Risk of mycosis fungoides in psoriatic patients: a critical review

Risk of mycosis fungoides in psoriatic patients: a critical review

Immunotherapy for Cutaneous T-Cell Lymphoma: Current Landscape and Future Developments

Mycosis fungoides

Contact Info

Product

Resources

About